Continuing recent consolidations in the pharmaceutical industry is the report that the giant GlaxoSmithKline (or GSK) are to purchase Stiefel. Stiefel is the manufacturer of Rosac Wash and Rosac cream with Sunscreens. Stiefel is also the makers of Rosasol – a formulation of metronidazole with SPF15 available in Canada.
Stiefel is also a supporter of the National Rosacea Society, having offered unrestricted educational grants in the past.
Rosac is a topical preparation that combines 2 sunscreens with sodium sulfacetamide and sulfur.
GSK is not known for its rosacea products, perhaps the closest they have ventured so far is Spectro Jel.
WSJ: GlaxoSmithKline May Buy Stiefel for $3B
GlaxoSmithKline (GSK: 30.61, -0.25, -0.81%) is close to a deal to acquire Stiefel Laboratories for around $3 billion, The Wall Street Journal reported, citing people familiar with the matter.
Major pharmaceutical industry players are rushing to merge to beat back growing competition from generic drug makers and replenish their product pipelines. So far this year a number of deals have been announced, such as Pfizer’s (PFE: 14.18, 0.29, 2.09%) pending buyout of Wyeth (WYE: 43.24, 0.37, 0.86%) and Merck’s (MRK: 25.7963, -0.0537, -0.21%) pending takeover of Schering-Plough (SGP: 23.4, 0.13, 0.56%).
